Clinical Trials Logo

Clinical Trial Summary

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 CAR NK cells in patients with relapsed refractory B cell lymphoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03690310
Study type Interventional
Source Allife Medical Science and Technology Co., Ltd.
Contact
Status Not yet recruiting
Phase Early Phase 1
Start date March 2019
Completion date November 2021

See also
  Status Clinical Trial Phase
Recruiting NCT06158386 - Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma Phase 2
Recruiting NCT05003141 - PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Phase 1
Recruiting NCT04300998 - Study of CAR-T Therapy in Older Patients
Not yet recruiting NCT03692767 - Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma Early Phase 1
Recruiting NCT06378190 - Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology Phase 1/Phase 2
Not yet recruiting NCT03824951 - Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma Early Phase 1
Not yet recruiting NCT03824964 - Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma Early Phase 1